341 related articles for article (PubMed ID: 15747376)
41. Response to tyrosine kinase inhibitors in chronic myeloid leukemia: experience from a west Asian developing country.
Ali MD; Badi AI; Al-Zebari SS; Al-Allawi NA
Int J Hematol; 2014 Sep; 100(3):274-80. PubMed ID: 25085252
[TBL] [Abstract][Full Text] [Related]
42. Kinase-independent mechanisms of resistance of leukemia stem cells to tyrosine kinase inhibitors.
Ichim CV
Stem Cells Transl Med; 2014 Apr; 3(4):405-15. PubMed ID: 24598782
[TBL] [Abstract][Full Text] [Related]
43. MDR1 expression predicts outcome of Ph+ chronic phase CML patients on second-line nilotinib therapy after imatinib failure.
Agrawal M; Hanfstein B; Erben P; Wolf D; Ernst T; Fabarius A; Saussele S; Purkayastha D; Woodman RC; Hofmann WK; Hehlmann R; Hochhaus A; Müller MC
Leukemia; 2014 Jul; 28(7):1478-85. PubMed ID: 24472814
[TBL] [Abstract][Full Text] [Related]
44. Tyrosine kinase inhibitors as initial therapy for patients with chronic myeloid leukemia in accelerated phase.
Ohanian M; Kantarjian HM; Quintas-Cardama A; Jabbour E; Abruzzo L; Verstovsek S; Borthakur G; Ravandi F; Garcia-Manero G; Champlin R; Pierce S; Alattar ML; Trinh LX; Luthra R; Ferrajoli A; Kadia T; O'Brien S; Cortes JE
Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):155-162.e1. PubMed ID: 24332214
[TBL] [Abstract][Full Text] [Related]
45. A single nucleotide polymorphism in cBIM is associated with a slower achievement of major molecular response in chronic myeloid leukaemia treated with imatinib.
Augis V; Airiau K; Josselin M; Turcq B; Mahon FX; Belloc F
PLoS One; 2013; 8(11):e78582. PubMed ID: 24223824
[TBL] [Abstract][Full Text] [Related]
46. MIP-1α/CCL3-mediated maintenance of leukemia-initiating cells in the initiation process of chronic myeloid leukemia.
Baba T; Naka K; Morishita S; Komatsu N; Hirao A; Mukaida N
J Exp Med; 2013 Nov; 210(12):2661-73. PubMed ID: 24166712
[TBL] [Abstract][Full Text] [Related]
47. Potential mechanisms of disease progression and management of advanced-phase chronic myeloid leukemia.
Jabbour EJ; Hughes TP; Cortés JE; Kantarjian HM; Hochhaus A
Leuk Lymphoma; 2014 Jul; 55(7):1451-62. PubMed ID: 24050507
[TBL] [Abstract][Full Text] [Related]
48. Resistance to tyrosine kinase inhibition therapy for chronic myelogenous leukemia: a clinical perspective and emerging treatment options.
Jabbour EJ; Cortes JE; Kantarjian HM
Clin Lymphoma Myeloma Leuk; 2013 Oct; 13(5):515-29. PubMed ID: 23890944
[TBL] [Abstract][Full Text] [Related]
49. Biomarkers for determining the prognosis in chronic myelogenous leukemia.
Sweet K; Zhang L; Pinilla-Ibarz J
J Hematol Oncol; 2013 Jul; 6():54. PubMed ID: 23870290
[TBL] [Abstract][Full Text] [Related]
50. Activity of histone deacetylase inhibitors and an Aurora kinase inhibitor in BCR-ABL-expressing leukemia cells: Combination of HDAC and Aurora inhibitors in BCR-ABL-expressing cells.
Okabe S; Tauchi T; Tanaka Y; Kimura S; Maekawa T; Ohyashiki K
Cancer Cell Int; 2013 Apr; 13(1):32. PubMed ID: 23556431
[TBL] [Abstract][Full Text] [Related]
51. Nilotinib is associated with a reduced incidence of BCR-ABL mutations vs imatinib in patients with newly diagnosed chronic myeloid leukemia in chronic phase.
Hochhaus A; Saglio G; Larson RA; Kim DW; Etienne G; Rosti G; De Souza C; Kurokawa M; Kalaycio ME; Hoenekopp A; Fan X; Shou Y; Kantarjian HM; Hughes TP
Blood; 2013 May; 121(18):3703-8. PubMed ID: 23502220
[TBL] [Abstract][Full Text] [Related]
52. Current practices in the management of chronic myeloid leukemia.
Kantarjian HM; Larson RA; Cortés JE; Deering KL; Mauro MJ
Clin Lymphoma Myeloma Leuk; 2013 Feb; 13(1):48-54. PubMed ID: 23103085
[TBL] [Abstract][Full Text] [Related]
53. Mutated BCR-ABL generates immunogenic T-cell epitopes in CML patients.
Cai A; Keskin DB; DeLuca DS; Alonso A; Zhang W; Zhang GL; Hammond NN; Nardi V; Stone RM; Neuberg D; Sidney J; Brusic V; Wu CJ
Clin Cancer Res; 2012 Oct; 18(20):5761-72. PubMed ID: 22912393
[TBL] [Abstract][Full Text] [Related]
54. Further phenotypic characterization of the primitive lineage- CD34+CD38-CD90+CD45RA- hematopoietic stem cell/progenitor cell sub-population isolated from cord blood, mobilized peripheral blood and patients with chronic myelogenous leukemia.
Wisniewski D; Affer M; Willshire J; Clarkson B
Blood Cancer J; 2011 Sep; 1(9):e36. PubMed ID: 22829197
[TBL] [Abstract][Full Text] [Related]
55. Genetic mechanisms of chronic myeloid leukemia blastic transformation.
Skorski T
Curr Hematol Malig Rep; 2012 Jun; 7(2):87-93. PubMed ID: 22328017
[TBL] [Abstract][Full Text] [Related]
56. Evolution of therapies for chronic myelogenous leukemia.
Santos FP; Kantarjian H; Quintás-Cardama A; Cortes J
Cancer J; 2011; 17(6):465-76. PubMed ID: 22157290
[TBL] [Abstract][Full Text] [Related]
57. Enhanced ABL-inhibitor-induced MAPK-activation in T315I-BCR-ABL-expressing cells: a potential mechanism of altered leukemogenicity.
Härtel N; Klag T; Hanfstein B; Mueller MC; Schenk T; Erben P; Hochhaus A; La Rosée P
J Cancer Res Clin Oncol; 2012 Feb; 138(2):203-12. PubMed ID: 22089930
[TBL] [Abstract][Full Text] [Related]
58. Dasatinib: a review of its use in the treatment of chronic myeloid leukaemia and Philadelphia chromosome-positive acute lymphoblastic leukaemia.
McCormack PL; Keam SJ
Drugs; 2011 Sep; 71(13):1771-95. PubMed ID: 21902298
[TBL] [Abstract][Full Text] [Related]
59. Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?
Soverini S; Rosti G; Iacobucci I; Baccarani M; Martinelli G
Oncologist; 2011; 16(6):868-76. PubMed ID: 21632458
[TBL] [Abstract][Full Text] [Related]
60. Monitoring response and resistance to treatment in chronic myeloid leukemia.
Assouline S; Lipton JH
Curr Oncol; 2011 Apr; 18(2):e71-83. PubMed ID: 21505592
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
